Provides civil and criminal immunity for the distribution or use of Naloxone and other opioid antagonists beyond their shelf-life end date

House Bill 907 creates a new provision in Louisiana Revised Statutes Chapter 40 that provides immunity from civil and criminal liability for the distribution and administration of naloxone and other opioid antagonists that have exceeded their labeled shelf-life end dates. The statute establishes two separate immunity regimes: first, it prohibits criminal or civil liability for persons who prescribe, dispense, distribute, or furnish expired opioid antagonists solely on the basis that the shelf-life end date has passed, and second, it grants broader immunity to any person acting in good faith who furnishes or administers such medications to someone reasonably believed to be experiencing an opioid-related overdose, except where gross negligence or willful or wanton misconduct is demonstrated. The statute defines shelf-life end date by reference to the federal regulation at 21 CFR part 211.137 and includes a carve-out preserving the obligation of federally certified healthcare providers, facilities, and entities to comply with applicable federal regulations.

This legislation directly benefits healthcare professionals, emergency responders, community organizations, and individuals who may administer opioid antagonists in overdose situations. Healthcare practitioners granted immunity under the statute are also protected from disciplinary action by professional licensing boards, eliminating a parallel avenue for professional sanctions. The practical effect is to remove barriers to the distribution and use of expired naloxone in emergency contexts, which addresses real-world scenarios where naloxone may remain efficacious beyond its labeled expiration date but is unavailable or financially inaccessible to those experiencing overdose. First responders, harm reduction organizations, and healthcare facilities will have legal clarity that they may use expired opioid antagonists without facing liability unless their conduct rises to the level of gross negligence or willful misconduct.

The statute operates within Louisiana's prescription and pharmaceutical regulation framework found in Title 40 of the Louisiana Revised Statutes. Its immunity provisions create an exception to general principles of product liability and medical malpractice law by establishing a safe harbor for good-faith emergency use of expired pharmaceuticals. The statute's reference to federal regulatory requirements in 21 CFR part 211.137 incorporates federal pharmacy standards by reference and preserves federal compliance obligations for federally regulated entities, ensuring the state law does not conflict with or preempt federal regulatory authority over drug stability and shelf-life determinations. This reflects the federalism structure governing pharmaceutical regulation and acknowledges that some entities operating under federal certification cannot be exempted from federal requirements by state law.